Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

Medigen In-licenses Asian Rights for Cancer Drug

publication date: Mar 19, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Medigen Biotechnology Corp., a biotech company based in Taiwan, has in-licensed key rights for a cancer drug from Oncolys BioPharma, Inc. of Japan. Medigen will pay up to $198.9 million, including milestones, for the right to develop OBP-301 for liver cancer or an alternative indication. Plus, upon completing Phase II studies, Medigen will also have the option to acquire the Asian rights, including China and Japan, to the drug for all indications. More details...




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners